This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 23/6/1111    most recent 01.ATV.0000074879.19006.51v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tuleja, E. Articles by Szczeklik, A. Search for Related Content PubMed PubMed Citation Articles by Tuleja, E. Articles by Szczeklik, A. Related Collections ACE/Angiotension receptors Clinical Studies Catheter-based coronary and valvular interventions: other

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:1111.)
© 2003 American Heart Association, Inc.

Thrombosis

Effects of Cyclooxygenases Inhibitors on Vasoactive Prostanoids and Thrombin Generation at the Site of Microvascular Injury in Healthy Men

Ewa Tuleja; Filip Mejza; Adam Cmiel; Andrzej Szczeklik

From the Department of Medicine (E.T., F.M., A.S.), Jagiellonian University School of Medicine and Department of Applied Mathematics (A.C.), University of Mining and Metallurgy, Cracow, Poland.

Correspondence to Andrzej Szczeklik MD, PhD, Department of Medicine, Jagiellonian University School of Medicine, 31-066 Krakow, ul.Skawinska 8, Poland. E-mail mmszczek{at}cyf-kr.edu.pl

Objective— Balance between vasoactive prostanoids that contribute to homeostasis of the circulatory system can be affected by cyclooxygenases inhibitors. Results of a recent large clinical trial show that myocardial infarction was more frequent among patients with rheumatoid arthritis treated with the selective cyclooxygenase-2 inhibitor rofecoxib compared with those treated with naproxen. Whether this difference was attributable to deleterious cardiovascular effects of rofecoxib or cardioprotective effects of naproxen has not been determined. We tested the hypothesis that naproxen, contrary to rofecoxib, exerts antithrombotic effects.

Methods and Results— Forty-five healthy men were randomized to receive a 7-day treatment with rofecoxib (50 mg/d), naproxen (1000 mg/d), aspirin (75 mg/d), or diclofenac (150 mg/d). Formation of thromboxane, prostacyclin, and thrombin in the bleeding-time blood at the site of standardized microvascular injury was assessed before and after treatment. Naproxen, like aspirin, caused significant reduction of both thromboxane and prostacyclin, whereas diclofenac depressed prostacyclin synthesis but had no effect on tromboxane formation. Naproxen and aspirin significantly suppressed thrombin generation. Diclofenac showed a similar tendency, which did not reach statistical significance. Rofecoxib had no effect on any variables measured.

Conclusions— In healthy men, naproxen exerts an antithrombotic effect at least as potent as aspirin, whereas rofecoxib does not affect hemostatic balance.

Key Words: myocardial infarction • risk factors • cyclooxygenase inhibitors • prostaglandins • thrombin

This article has been cited by other articles:

				L. A. Holowatz, J. D. Jennings, J. A. Lang, and W. L. Kenney Ketorolac alters blood flow during normothermia but not during hyperthermia in middle-aged human skin J Appl Physiol, October 1, 2009; 107(4): 1121 - 1127. [Abstract] [Full Text] [PDF]

				L. A. Holowatz and W. L. Kenney Chronic low-dose aspirin therapy attenuates reflex cutaneous vasodilation in middle-aged humans J Appl Physiol, February 1, 2009; 106(2): 500 - 505. [Abstract] [Full Text] [PDF]

				C. H. Hennekens and S. Borzak Cyclooxygenase-2 Inhibitors and Most Traditional Nonsteroidal Anti-inflammatory Drugs Cause Similar Moderately Increased Risks of Cardiovascular Disease Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2008; 13(1): 41 - 50. [Abstract] [PDF]